CN113952467A - Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof - Google Patents

Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof Download PDF

Info

Publication number
CN113952467A
CN113952467A CN202010706564.2A CN202010706564A CN113952467A CN 113952467 A CN113952467 A CN 113952467A CN 202010706564 A CN202010706564 A CN 202010706564A CN 113952467 A CN113952467 A CN 113952467A
Authority
CN
China
Prior art keywords
polypeptide
endometriosis
preparation
product obtained
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010706564.2A
Other languages
Chinese (zh)
Inventor
赵华山
张键
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Priority to CN202010706564.2A priority Critical patent/CN113952467A/en
Priority to PCT/CN2020/129877 priority patent/WO2022016751A1/en
Publication of CN113952467A publication Critical patent/CN113952467A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof

Abstract

The invention discloses a molecular diagnosis and treatment preparation for endometriosis and a preparation method and application thereof. The preparation comprises the following components: 1) an effector component, i.e. a diagnostic compound and/or a drug for the treatment of endometriosis; 2) a targeting module, i.e., a polypeptide with target recognition ability; the polypeptide comprises one or more combined polypeptides in the following sequences or derivatives of one or more combined polypeptides in the following sequences, SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5 and SEQ ID No. 6. The invention is suitable for the diagnosis and/or treatment of human endometriosis diseases, and can also be used as a research tool for endometriosis model experimental animals.

Description

Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof
Technical Field
The invention belongs to the field of medical cytobiology, and relates to an endometriosis molecular diagnosis and treatment preparation as well as a preparation method and application thereof.
Background
Endometriosis is a clinically common gynecological problem with ectopic growth of active endometrial tissues in a non-uterine environment. At present, the pathogenesis of the disease is not clear, so that a high-efficiency direct tool means is lacked for diagnosing and treating the disease, early detection is undoubtedly the prerequisite for intervention and treatment of the disease, and a reagent or a medicament with diagnostic value and therapeutic value is transported to an endometriosis focus in the simplest way by utilizing a polypeptide with target recognition capability and the like, so that the diagnosis, intervention and treatment idea is very valuable.
Disclosure of Invention
In order to solve the problems in the background art, the invention aims to provide an endometriosis molecular diagnosis and treatment preparation, and a preparation method and application thereof.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the invention provides a molecular diagnosis and treatment preparation for endometriosis, which comprises the following components: 1) an effector component, i.e. a diagnostic compound and/or a drug for the treatment of endometriosis; 2) a targeting module, i.e., a polypeptide with target recognition ability;
the polypeptide comprises the polypeptide of one or more of the following sequences in combination, or the derivative of the polypeptide of one or more of the following sequences in combination,
Figure BDA0002595006380000011
the polypeptide is modified on a diagnosis and/or treatment carrier to realize the specific recognition of the polypeptide on lesion tissues, so that a disease intervention tool for diagnosis and treatment is obtained.
Further, the derivative is a product obtained by modifying the tail end or the side chain of the polypeptide, or a product obtained by modifying the polypeptide with a fluorescent group, or a product obtained by isotopic labeling of the polypeptide, or a product obtained by phosphorylating and modifying the polypeptide, or a product obtained by cyclizing and modifying the polypeptide based on a disulfide bond, or a product obtained by labeling the polypeptide with biotin, or a product obtained by modifying the polypeptide with a photosensitizer, or a product obtained by modifying the polypeptide with azide, or a product obtained by modifying the polypeptide with PEG, or a product obtained by modifying the polypeptide with methylation, or a product obtained by modifying the polypeptide with a fluorescence quenching group, or a product obtained by modifying the polypeptide with a protein coupling, or a product obtained by modifying the polypeptide with a small molecular compound.
Further, the polypeptide is subjected to terminal or side chain modification including but not limited to N-terminal acetylation modification and C-terminal amination modification.
Further, fluorescent dyes used in the labeled modification of the fluorescent group of the polypeptide include, but are not limited to, FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7, which are modified for fluorescent detection purposes.
Further, isotopes used in isotopic labeling of said polypeptides include, but are not limited to13C, the modification is used for tracking purposes.
Further, phosphorylation modifications performed by the polypeptide include, but are not limited to, p-Ser, p-Thr, p-Tyr.
Further, the polypeptide is labeled with biotin for localization detection purposes and the like.
Further, the polypeptide is photosensitizer modified to facilitate the preparation of photosensitive formulations.
Further, the polypeptide is subjected to azide modification, which is beneficial to secondary ligation reaction.
Further, the polypeptide is modified by PEG and is used for preparing a drug carrier.
The polypeptide can be autonomously synthesized by general organic chemical laboratory conditions, and can also be industrially synthesized by conventional commercial reagent companies, namely, the polypeptide is synthesized by a solid phase method, and the synthesis of the directional amino acid chain is realized by the condensation reaction between different amino acids on resin. The derivative of the polypeptide then applies the desired modifying group after the amino acids have been linked.
Further, the diagnostic compound includes a near infrared dye.
Further, the near infrared region dyes include, but are not limited to, Cy5, Cy7, indocyanine green.
Further, the near infrared region dye is indocyanine green.
Further, the drug for treating endometriosis includes a therapeutic antibody, and a therapeutic drug for endometriosis which is currently available.
Furthermore, the therapeutic drug for endometriosis is a drug which has a small molecular weight, appropriate water solubility, and high biosafety and stability.
Further, the treatment medicament for endometriosis comprises one or a combination of at least two of progestogen medicament, androgen medicament and gonadotropin releasing hormone agonist;
preferably, the progestogen drugs include previtamin, progesterone, entamedone, progesterone caproate;
preferably, the androgen medication comprises danazol;
preferably, the gonadotropin releasing hormone agonist comprises goserelin.
The invention provides a preparation method of the endometriosis molecular diagnosis and treatment preparation, which comprises the steps of connecting and assembling an effect component and a targeting component by a conventional method to obtain the endometriosis molecular diagnosis and treatment preparation; the molar ratio of the effector component to the targeting component is 1: 0-1: 1, excluding 1: 0, preferably 1: 0.5-1: 1.
further, the preparation method of the endometriosis molecular diagnosis and treatment preparation comprises the following steps:
a) preparing an effect component: preparing a diagnostic compound and/or a medicament for the treatment of endometriosis;
b) preparation of targeting module: preparing the polypeptide by a conventional method, or a modified polypeptide derivative;
c) the effector component and the targeting component are connected: the connection assembly is carried out by a conventional method (such as an EDC method and the like), and the molar ratio of the effector component to the targeting component is 1: 0-1: 1 (excluding 1: 0), preferably 1: 0.5-1: 1. if the effect component is also polypeptide substance, the complete diagnosis and treatment preparation can be directly synthesized by using a proper polypeptide linker structure between the two components by using a conventional polypeptide synthesis method. Generally, the mixture is stored at 4 ℃ for standby or prepared as before.
The endometriosis molecular diagnosis and treatment preparation is applied to preparation of medicines for diagnosing and/or treating endometriosis.
The invention has the beneficial effects that:
(1) the molecular diagnosis and treatment preparation for endometriosis provided by the invention can be used for diagnosing endometriosis.
(2) The molecular diagnosis and treatment preparation for endometriosis provided by the invention can be used for treating endometriosis.
(3) The endometriosis molecular diagnosis and treatment preparation provided by the invention has the characteristics of simple synthesis process and low cost because the whole size is maintained at the level of a small molecular compound, and is favorable for commercialized application.
(4) The compound or the medicine with diagnostic or therapeutic effect is added with the targeting molecule which specifically recognizes the ectopic endometrial tissue, so that the compound or the medicine with diagnostic value or therapeutic value is targeted and administered to the specifically recognized focal tissue. The molecular diagnosis and treatment preparation for endometriosis is a modified small molecular compound, so that the stability is high and the in vivo transportation is facilitated. The invention is suitable for diagnosing and treating human endometriosis diseases, and can also be used as a research tool for endometriosis modeling experimental animals.
Drawings
Fig. 1 is a graph of the in-vivo imaging effect of indocyanine green in the example of the present invention.
Detailed Description
For a better understanding of the present invention, the following examples are given to illustrate the present invention, but the present invention is not limited to the following examples.
The invention takes the polypeptide sequence of SEQ ID No.1 as an example.
Example 1: preparation of the polypeptide sequence of SEQ ID No.1
The polypeptide sequence is industrially synthesized by a specialized polypeptide preparation company.
The method is based on solid phase synthesis of resin, polypeptide molecules are synthesized from C end to N end through condensation reaction between amino acids, and modification is carried out by using azidoacetic acid.
Example 2: preparation of molecular diagnosis and treatment preparation for endometriosis
The effector component was selected from indocyanine green dye, available from commercial chemicals, and was selected to be modified with DBCO linker for subsequent attachment to the polypeptide sequence. Targeting module part, the polypeptide sequence prepared in example 1 was selected. The effector component and the targeting component are arranged in a mode of 1: mixing at 0.5 mol ratio, mixing, and storing at 4 deg.C.
Example 3: preparation of mouse animal model with endometriosis
Taking an adult female mouse, after disinfection and anesthesia, taking an orthotopic endometrial tissue, cutting into small pieces (2 mm X2 mm), fixedly inoculating the small pieces near an mesenteric blood vessel, suturing a wound, then statically culturing the mouse, freely taking drinking water, and after one month, growing vesicles to consider that molding is successful.
Example 4: fluorescent signal detection under small animal imager
The diagnosis and treatment preparation prepared in the example 2 is injected into the tail vein of the successfully molded mouse, after 24 hours, the mouse is subjected to respiratory anesthesia, then the mouse is placed in a small animal imager, and a fluorescence signal is observed in a living body under the respiratory anesthesia state, wherein the excitation wavelength of fluorescence is between 600 and 900 nanometers.
Based on the characteristic of the targeting component for specifically identifying the ectopic endometrial tissue and the long-wavelength imaging characteristic of indocyanine green (as shown in figure 1), the preparation can be applied to imaging diagnosis of endometriosis focus, so that the purpose of early diagnosis is achieved.
In conclusion, the molecular diagnosis and treatment preparation for endometriosis provided by the application can be used for the diagnosis and treatment purpose of endometriosis.
The above description is only a specific embodiment of the present invention, and not all embodiments, and any equivalent modifications of the technical solutions of the present invention, which are made by those skilled in the art through reading the present specification, are covered by the claims of the present invention.
SEQUENCE LISTING
<110> Shenzhen advanced technology research institute
<120> endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof
<130> CP120010185C
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 28
<212> PRT
<213> Artificial sequence
<400> 1
Glu Asp Val Lys Asp Ile Asn Phe Asp Thr Lys Glu Lys Phe Leu Ala
1 5 10 15
Gly Cys Leu Ile Val Ser Phe His Glu Gly Lys Cys
20 25
<210> 2
<211> 30
<212> PRT
<213> Artificial sequence
<400> 2
Gly Lys Lys Thr Gln Glu Leu Lys Asn Ile Arg Thr Asn Ser Glu Leu
1 5 10 15
Leu Lys Glu Trp Ile Ile Ala Ala Phe His Glu Gly Lys Cys
20 25 30
<210> 3
<211> 20
<212> PRT
<213> Artificial sequence
<400> 3
Leu Lys Pro Ser His Glu Lys Lys Asn Asp Asp Asn Gly Lys Lys Leu
1 5 10 15
Cys Lys Ala Cys
20
<210> 4
<211> 27
<212> PRT
<213> Artificial sequence
<400> 4
Glu Asp Val Lys Asp Ile Asn Phe Asp Thr Lys Glu Lys Phe Leu Ala
1 5 10 15
Gly Cys Leu Ile Val Ser Phe His Glu Gly Lys
20 25
<210> 5
<211> 29
<212> PRT
<213> Artificial sequence
<400> 5
Gly Lys Lys Thr Gln Glu Leu Lys Asn Ile Arg Thr Asn Ser Glu Leu
1 5 10 15
Leu Lys Glu Trp Ile Ile Ala Ala Phe His Glu Gly Lys
20 25
<210> 6
<211> 19
<212> PRT
<213> Artificial sequence
<400> 6
Leu Lys Pro Ser His Glu Lys Lys Asn Asp Asp Asn Gly Lys Lys Leu
1 5 10 15
Cys Lys Ala

Claims (10)

1. An endometriosis molecular diagnosis and treatment preparation is characterized by comprising the following components: 1) an effector component, i.e. a diagnostic compound and/or a drug for the treatment of endometriosis; 2) a targeting module, i.e., a polypeptide with target recognition ability;
the polypeptide comprises the polypeptide of one or more of the following sequences in combination, or the derivative of the polypeptide of one or more of the following sequences in combination,
EDVKDINFDTKEKFLAGCLIVSFHEGKC SEQ ID No.1
GKKTQELKNIRTNSELLKEWIIAAFHEGKC SEQ ID No.2
LKPSHEKKNDDNGKKLCKAC SEQ ID No.3
EDVKDINFDTKEKFLAGCLIVSFHEGK SEQ ID No.4
GKKTQELKNIRTNSELLKEWIIAAFHEGK SEQ ID No.5
LKPSHEKKNDDNGKKLCKA SEQ ID No.6。
2. the molecular diagnostic and therapeutic agent for endometriosis according to claim 1, wherein said derivative is a product obtained by modifying a terminal or a side chain of a polypeptide, or the product obtained by the labeling modification of the fluorescent group of the polypeptide or the product obtained by the isotopic labeling of the polypeptide, or phosphorylation modification of the polypeptide, or disulfide bond-based cyclization modification of the polypeptide, or the product obtained by labeling the polypeptide with biotin or the product obtained by modifying the polypeptide with photosensitizer, or the product obtained by performing azide modification on the polypeptide, or the product obtained by performing PEG modification on the polypeptide, or a product obtained by performing methylation modification on the polypeptide, or a product obtained by performing fluorescence quenching group modification on the polypeptide, or a product obtained by modifying the polypeptide through protein coupling, or a product obtained by modifying the polypeptide through a small molecular compound;
preferably, the polypeptide is subjected to terminal or side chain modification including N-terminal acetylation modification and C-terminal amination modification;
preferably, fluorescent dyes used in the labeled modification of the fluorescent group of the polypeptide include FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy 7;
preferably, the polypeptideIsotopes used in carrying out isotopic labeling include13C；
Preferably, the phosphorylation modifications performed by the polypeptide include p-Ser, p-Thr, p-Tyr.
3. The endometriosis molecular diagnostic or therapeutic preparation according to claim 1, wherein said diagnostic compound comprises a dye in the near infrared region.
4. The molecular diagnostic and therapeutic preparation for endometriosis according to claim 3, wherein the dye in the near infrared region comprises Cy5, Cy7, indocyanine green.
5. The molecular diagnostic and therapeutic preparation for endometriosis according to claim 4, wherein the dye in the near infrared region is indocyanine green.
6. The molecular diagnostic and therapeutic agent for endometriosis according to claim 1, wherein the drug for endometriosis comprises a therapeutic antibody, a currently available therapeutic drug for endometriosis.
7. The molecular diagnostic and therapeutic agent for endometriosis according to claim 6, wherein the therapeutic agent for endometriosis is a drug having a small molecular weight, an appropriate water solubility, and high biosafety and stability.
8. The molecular diagnostic and therapeutic preparation for endometriosis according to claim 7, wherein the therapeutic drug for endometriosis comprises one or a combination of at least two of progestogen drugs, androgen drugs, gonadotropin releasing hormone agonists;
preferably, the progestogen drugs include previtamin, progesterone, entamedone, progesterone caproate;
preferably, the androgen medication comprises danazol;
preferably, the gonadotropin releasing hormone agonist comprises goserelin.
9. A preparation method of a molecular diagnosis and treatment preparation for endometriosis is characterized in that an effect component and a targeting component are connected and assembled by a conventional method to obtain the molecular diagnosis and treatment preparation for endometriosis; the molar ratio of the effector component to the targeting component is 1: 0-1: 1, excluding 1: 0, preferably 1: 0.5-1: 1.
10. use of a molecular diagnostic and therapeutic preparation according to any one of claims 1 to 8 for the preparation of a medicament for the diagnosis and/or treatment of endometriosis.
CN202010706564.2A 2020-07-21 2020-07-21 Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof Pending CN113952467A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010706564.2A CN113952467A (en) 2020-07-21 2020-07-21 Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof
PCT/CN2020/129877 WO2022016751A1 (en) 2020-07-21 2020-11-18 Molecular diagnosis and treatment formulation for endometriosis, preparation method therefor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010706564.2A CN113952467A (en) 2020-07-21 2020-07-21 Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN113952467A true CN113952467A (en) 2022-01-21

Family

ID=79459841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010706564.2A Pending CN113952467A (en) 2020-07-21 2020-07-21 Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN113952467A (en)
WO (1) WO2022016751A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116200485A (en) * 2022-11-01 2023-06-02 广东省生殖科学研究所(广东省生殖医院) Application of methylation site in endometriosis diagnosis and typing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108567973A (en) * 2017-10-17 2018-09-25 中国科学院深圳先进技术研究院 A kind of placenta sample chondroitin sulfate A (CSA) immune composition and application
CN109568597A (en) * 2017-09-28 2019-04-05 中国科学院深圳先进技术研究院 Target the polypeptide drugs conjugate and its preparation method and application of placenta sample chondroitin sulfate A (CSA)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605260VA (en) * 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
CN109387627B (en) * 2018-10-16 2021-09-24 中国科学院深圳先进技术研究院 Reagent method for screening and early diagnosis of cancer based on placenta-like chondroitin sulfate A

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109568597A (en) * 2017-09-28 2019-04-05 中国科学院深圳先进技术研究院 Target the polypeptide drugs conjugate and its preparation method and application of placenta sample chondroitin sulfate A (CSA)
CN108567973A (en) * 2017-10-17 2018-09-25 中国科学院深圳先进技术研究院 A kind of placenta sample chondroitin sulfate A (CSA) immune composition and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMY WINSHIP等: "Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration", 《INTERNATIONAL JOURNAL OF ONCOLOGY》 *
PLI´NIO T. BERARDO等: "Composition of sulfated glycosaminoglycans and immunodistribution of chondroitin sulfate in deeply infiltrating endometriosis affecting the rectosigmoid", 《MICRON》 *
TADAHISA MIKAMI等: "Biosynthesis and function of chondroitin sulfate", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
魏孟梅等: "基质金属蛋白酶-9及金属蛋白酶组织抑制剂-1在孕鼠胎盘形成中期的表达模式", 《四川动物》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116200485A (en) * 2022-11-01 2023-06-02 广东省生殖科学研究所(广东省生殖医院) Application of methylation site in endometriosis diagnosis and typing
CN116200485B (en) * 2022-11-01 2023-12-15 广东省生殖科学研究所(广东省生殖医院) Application of methylation site in endometriosis diagnosis and typing

Also Published As

Publication number Publication date
WO2022016751A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
CN101939384A (en) Peptide imaging agents
CN113004371A (en) Prostate specific membrane antigen targeting compound with long circulation half-life period and preparation method and application thereof
KR20200104524A (en) Novel cell penetrating peptides and use thereof
CN114288414A (en) Polypeptide crossing blood brain barrier, derivative and application thereof
CN114306630A (en) Polypeptide targeting brain tumor, derivative and application thereof
CN113292635B (en) Polypeptide targeting CD47 and application thereof
CN111228508B (en) Multi-target anti-tumor polypeptide drug conjugate and preparation method and application thereof
WO2015196944A1 (en) Gnrh analog-cytotoxic molecule conjugate and preparation method and use thereof
CN113952467A (en) Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof
CN112961215B (en) Polypeptide and tumor targeting peptide, tumor detection reagent, tumor surgery navigation contrast medium and tumor targeting drug thereof
CN111233976B (en) Tumor targeting polypeptide and application thereof in preparation of polypeptide drug conjugate
CN104870470B (en) People&#39;s relaxins analog, its pharmaceutical composition and its in application pharmaceutically
JP7456676B2 (en) Novel cell-penetrating peptides and their uses
CN113599504A (en) Carrier-free protein intracellular delivery prodrug and preparation method and application thereof
CN106163569A (en) Neurotensin molecule of activation and application thereof
EP3952862A2 (en) Ir700 nanocompositions for cardiac therapies and applications
CN117098770A (en) Polypeptide compound for SORT1 and drug conjugate thereof
JP5103748B2 (en) Pharmaceutical composition
CN111234813B (en) Follicle granular cell near-infrared fluorescent probe Nirova-1 and preparation method and application thereof
CN109922817A (en) The agent and method of relevant disease are had enough to meet the need to extracellular matrix for diagnosing and treating
CN107266929B (en) One kind is using Cyanine Dyes Fluorescence group as near infrared fluorescent dye of precursor skeleton structure and the preparation method and application thereof
CN111053922A (en) Follicle granular cell near-infrared fluorescent probe Nirova-2 and preparation method and application thereof
WO2022016375A1 (en) Ectopic endometrium recognition polypeptide, and derivative and use thereof
CN113967268A (en) Endometriosis focus targeted nano delivery system and preparation method and application thereof
CN113956331A (en) Ectopic endometrium recognition polypeptide and derivative and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220121

RJ01 Rejection of invention patent application after publication